Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00682448 · ClinicalTrials.gov registry record · Phase 4
Metformin for the Prevention of the Metabolic Side-effects of Zyprexa
A Phase 4 study, sponsored by Rush University Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
NCT00682448 is a Phase 4 study that has completed, run by Rush University Medical Center. The registered enrollment target is 25 participants.
The verdict
NCT00682448, a Phase 4 study, has completed, sponsored by Rush University Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
Study Summary
We hypothesize that metformin co-administered with olanzapine will be well tolerated and associated with significantly less insulin resistance, weight gain and dyslipidemia as compared to olanzapine plus placebo.
Interventions
- DRUG Placebo
- DRUG Metformin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2007-08 |
| Est. Completion | 2011-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00682448
The ClinicalTrials.gov registry entry for NCT00682448 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00682448 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00682448 about?
NCT00682448 is a clinical study titled "Metformin for the Prevention of the Metabolic Side-effects of Zyprexa". We hypothesize that metformin co-administered with olanzapine will be well tolerated and associated with significantly less insulin resistance, weight gain and dyslipidemia as compared to olanzapine plus placebo.
What is the current status of trial NCT00682448?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2007-08. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00682448?
The interventions under investigation include: Placebo (DRUG), Metformin (DRUG).
Who is sponsoring clinical trial NCT00682448?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.